molecules molecules molecules molecules molecules molecules

Clinical Pipeline

Sort by:
Indication
Molecule
Indication
Study
Line & Regimen
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Lung Cancer

Line & Regimen :
1L, PD-L1 ≥ 50%
dom + zim ± etruma vs. zim
Phase 1
Phase 1b
Phase 2
Phase 3
Line & Regimen> :
1L, 2L
dom + zim ± quemli ± chemo
Phase 1
Phase 1b
Phase 2
Phase 3
Line & Regimen> :
1L, 2L
dom ± zim ± etruma ± sacituzumab govitecan
Phase 1
Phase 1b
Phase 2
Phase 3
Line & Regimen> :
1L, PD-L1 ≥ 50%
dom + zim vs. pembro
Phase 1
Phase 1b
Phase 2
Phase 3
Line & Regimen> :
Stage III, unresectable, PD-L1≥1%
dom + durvalumab vs. durvalumab
Phase 1
Phase 1b
Phase 2
Phase 3
Line & Regimen> :
1L
dom + zim + chemo vs. pembro + chemo
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Prostate Cancer

Line & Regimen :
2L+
etruma + zim + doce vs. doce etruma + sacituzumab govitecan ± zim
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Colorectal Cancer

Line & Regimen> :
3L
etruma + zim + FOLFOX* vs. rego
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Pancreatic Cancer

Line & Regimen> :
2L
quemli + zim + gem/nab-pac
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Gastrointestinal Cancer

Line & Regimen> :
2L
dom ± zim ± quemli
Phase 1
Phase 1b
Phase 2
Phase 3
Line & Regimen> :
1L
dom + zim + chemo vs. nivo + chemo
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Advanced Malignancies, Including RCC

Line & Regimen :
2L+
AB521
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Healthy Participants

Line & Regimen :
AB521
Phase 1
Phase 1b
Phase 2
Phase 3
Molecule
Indication
Study
Line & Regimen
Phase 1
Phase 1b
Phase 2
Phase 3
Molecule:

Domvanalimab
(DOM)

FC-SILENT ANTI-TIGIT ANTIBODY

Indication:

Lung Cancer

Line & Regimen:
1L, PD-L1 ≥ 50%
dom + zim ± etruma vs. zim
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Lung Cancer

Line & Regimen:
1L, 2L
dom + zim ± quemli ± chemo
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Lung Cancer

Line & Regimen:
1L, 2L
dom ± zim ± etruma ± sacituzumab govitecan
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Lung Cancer

Line & Regimen:
1L, PD-L1 ≥ 50%
dom + zim vs. pembro
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Lung Cancer

Line & Regimen:
Stage III, unresectable, PD-L1≥1%
dom + durvalumab vs. durvalumab
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Lung Cancer

Line & Regimen:
1L
dom + zim + chemo vs. pembro + chemo
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Gastrointestinal Cancer

Line & Regimen:
1L
dom ± zim ± FOLFOX
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Gastrointestinal Cancer

Line & Regimen:
2L
dom ± zim ± quemli
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Gastrointestinal Cancer

Line & Regimen:
1L
dom + zim + chemo vs. nivo + chemo
Phase 1
Phase 1b
Phase 2
Phase 3
Molecule:

Quemliclustat

CD73 Inhibitor Small Molecule

Indication:

Lung Cancer

Line & Regimen:
1L, 2L
dom + zim ± quemli ± chemo
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

GASTROINTESTINAL CANCER

Line & Regimen:
2L
dom ± zim ± quemli
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Pancreatic Cancer

Line & Regimen:
1L
quemli + zim + gem/nab-pac vs. quemli + gem/nab-pac
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Pancreatic Cancer

Line & Regimen:
2L
quemli + zim + gem/nab-pac
Phase 1
Phase 1b
Phase 2
Phase 3
Molecule:

Etrumadenant
(ETRUMA)

Dual A2a/A2b Adenosine Receptor Antagonist Small Molecule

Indication:

Lung Cancer

Line & Regimen:
1L, PD-L1 ≥ 50%
dom + zim ± etruma vs. zim
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Lung Cancer

Line & Regimen:
1L, 2L
dom ± zim ± etruma ± sacituzumab govitecan
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Prostate Cancer

Line & Regimen:
2L
etruma + zim + doce vs. doce etruma + sacituzumab govitecan ± zim
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Colorectal Cancer

Line & Regimen:
2L
etruma + zim + FOLFOX* vs. FOLFOX*
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Colorectal Cancer

Line & Regimen:
3L
etruma + zim + FOLFOX* vs. rego
Phase 1
Phase 1b
Phase 2
Phase 3
Molecule:

AB521

HIF-2𝛂 Inhibitor

Indication:

Healthy Participants

Line & Regimen:
AB521
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Advanced Malignancies, including RCC

Line & Regimen:
2L+
AB521
Phase 1
Phase 1b
Phase 2
Phase 3
Key Compounds Being Studied:
Etrumadenant

Dual A2aR/A2bR Antagonist Small Molecule

Quemliclustat

CD73 Inhibitor Small Molecule

Domvanalimab

anti-TIGIT mAb

Zimberelimab

anti-PD-1 mAb

Abbreviations:

atezo: atezolizumab; bev: bevacizumab; carbo/pem: carboplatin/pemetrexed; doce: docetaxel; dom: domvanalimab; enza: enzalutamide; etruma: etrumadenant; gem/nab-pac: gemcitabine/nab-paclitaxel; nivo: nivolumab; pembro: pembrolizumab; PLD: pegylated liposomal doxorubicin; quemli: quemliclustat; rego: regorafenib; SOC: standard of care; zim: zimberelimab

*+/- biologic, e.g. bevacizumab or biosimilar, will be included for all patients in whom it is not contraindicated.

Partnerships & Collaborations
molecules molecules

DISCOVERY PIPELINE

IMMUNO-ONCOLOGY TARGET

Molecule Icon

Anti-CD39

Exo-nucleotidase

CD39 is a key enzyme in removing ATP from the tumor microenvironment; increased ATP may enhance the adaptive immune response against tumors.1

Additional undisclosed targets.

CANCER CELL INTRINSIC TARGET

Molecule Icon

AXL Inhibitor

Tyrosine kinase

AXL overexpression is associated with tumor resistance to chemotherapy
and immunotherapy drugs.2

Additional undisclosed targets.

References: 1. Moesta et al. Targeting CD39 in Cancer. Nat Rev Immunol. Volume 20, pages 739–755 (2020). 2. Axelrod HD, Valkenburg KC, Amend SR, et al. AXL is a putative tumor suppressor and dormancy regulator in prostate cancer. Mol Cancer Res. 2019;17(2):356-369.